Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB’s Keppra and GlaxoSmithKline’s Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer’s Dilantin, Abbott’s Depakote, and Novartis’ Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline’s Trobalt/Potiga and Eisai’s Fycompa which both offer first-in-class mechanisms of action.

Highlights

Key Questions Answered

• Even with more than 20 AEDs on the market, there are still ~20% refractory patients. Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the epilepsy market?
• Several brands of AEDs are due for patent expiry. How will the patent expiries impact the epilepsy therapeutics market?
• The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?
• What governmental changes are likely to change the epilepsy treatment landscape in the markets researched? Which is the biggest growth market globally?

Key Findings

• New market entrants particularly Fycompa, Trobalt/Potiga and brivaracetam will increase competitiveness and cannibalize sales of existing AEDs.
• Drivers for market growth will include the introduction of the newer epilepsy drugs into the Asian market, particularly in Japan.
• Government cost-cutting measures will negatively impact epilepsy drug market in the EU

Scope

• Overview of epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized epilepsy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the epilepsy therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including ion channel modulators, GABA modulators, glutamate receptor antagonists, inflammation inhibitors, synaptic and gap junction blockers, sigma receptor agonists and acetylcholine modulators.
• Analysis of the current and future market competition in the global epilepsy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global epilepsy therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global epilepsy therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global epilepsy therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Know more about this report at – http://mrr.cm/ZaS

To browse more Diseases Reports visit:  

http://www.marketresearchreports.com/diseases

Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023, New Report Launched

Product Launches and Patent Expiries to Push Major Depressive Disorder Treatment Market through Fluctuating Growth Period by 2023

The therapeutics market for Major Depressive Disorder (MDD) will face a dynamic phase up until the end of 2023, thanks to the potential launch of new treatments following the patent expirations of top-selling products, according to new report.

The PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 report, the MDD treatment market achieved sales of approximately $9.3 billion in 2013 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan) and Australia. These sales will witness minimal growth by the end of 2023, reaching an estimated $9.7 billion, at a Compound Annual Growth Rate (CAGR) of 0.39%.

However, The forecasts that the market value will first undergo a decline until 2017, with sales dropping to $7.3 billion. This can be attributed mainly to the expirations of patents for Eli Lilly’s Cymbalta, Otsuka Pharmaceutical/BMS’ Abilify and AstraZeneca’s Seroquel XR.

The Senior Analyst covering Neurology, says: “Additionally, there are a number of significant needs in the depression therapeutics market that are yet to be addressed. These include the requirement for products that demonstrate improved efficacy, more favorable safety profiles and a rapid onset of antidepressant effects. Ample opportunity therefore exists for players looking to develop and potentially introduce therapies, which can address these unmet needs, into this arena.”

Publisher states that there are already seven products in the late-stage pipeline that could enter the MDD market during the forecast period. These include adjunctive therapies, such as Otsuka/Lundbeck’s brexpiprazole, Forest (Actavis)/Gedeon Richter/Mitsubishi Tanabe Pharma’s cariprazine, Alkermes’s ALKS-5461 and Naurex’s GLYX-13, along with antidepressant therapies, including Euthymics Bioscience’s amitifadine, Lundbeck/Takeda’s tedatioxetine and e-Therapeutics’ ETS6103.

The Senior Analyst continues: “All seven of these pipeline drugs show promise as safer and more efficacious treatments for MDD patients, while GLYX-13 and ETS6103 in particular boast the potential to provide rapid antidepressant effects.

“With their ability to address some of the MDD treatment market’s key unmet needs, we believe that these products’ launches could well spark its return to growth in 2018. Other driving factors behind the reversal in its decline will be the increasing uptake of Lundbeck/Takeda’s Brintellix, combined with the expanding number of MDD prevalent cases that we expect to see by the end of 2023.”

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 report provides an overview of Major Depressive Disorder (MDD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis and current treatment options. The key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the MDD therapeutics market.

Know more about this report at – http://mrr.cm/Za3

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update, New Report Launched

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update report Provide Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing a direct-acting antiviral (DAA), such as Gilead's Sovaldi (sofosbuvir) or Janssen's Olysio (simeprevir), along with pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and/or ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infections. Sovaldi and Olysio have largely replaced first-generation NS3/4A protease inhibitors, such as Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) due to their increased tolerability, efficacy, and shorter treatment duration. The entrance of next-generation , all-oral HCV therapies is expected to fundamentally alter the HCV treatment algorithm.

Highlights

Key Questions Answered

• How quickly, and to what extent, will interferon-sparing and all-oral regimens replace Incivek and Victrelis in the treatment algorithm?
• What role, if any, will interferon-based therapies have in the HCV treatment landscape over the next decade?
• Which novel HCV therapies will face adoption challenges in the market? What is the projected uptake of new drugs, such as Merck’s MK-5172/MK-8742, over the forecast period?
• Will the reduced pill burden and increased convenience of fixed-dose, all-oral combination therapies lead to their widespread uptake?
• How will pricing influence the use of next-generation DAAs?
• Which HCV regimen(s) in development are physicians most excited about?

Key Findings

• Patient awareness is anticipated to increase in response to government education and screening initiatives.
• Interferon use is predicted to drastically decrease over the next 10 years.
• The launch of next-generation, all-oral DAA regimens is expected to streamline the HCV treatment algorithm.
• The approval of more-tolerable HCV therapies is likely to result in patients deciding to undergo treatment (i.e., decrease in the warehouse effect).
• Fixed-dose combination therapies are expected to seize market share due to their reduced pill burden and convenience.

Scope

• Overview of hepatitis C virus (HCV), including epidemiology, etiology, general symptoms from infection, and national vaccination recommendations and guidelines.
• Annualized HCV therapeutics market revenue, annual cost of therapy, and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HCV market.
• Pipeline analysis: comprehensive data split across different phases, and emerging trends, specifically interferon-free therapies and fixed-dose combinations.
• Analysis of the current and future market competition in the global HCV therapeutics market. Insightful review of the key industry and governmental drivers, restraints and challenges.
• Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global HCV therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HCV market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global HCV therapeutics market from 2012-2022.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Know more about this report at – http://mrr.cm/Zaw

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

Allergic Rhinitis - Epidemiology Forecast to 2023, New Report Launched

Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis.

According to Publisher’s epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate of 0.17% during the forecast period.

In 2023, the US will have the highest number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases.

To forecast the total prevalent cases of allergic rhinitis in the 7MM, publisher epidemiologists selected only nationally representative studies that provided total prevalence of allergic rhinitis using uniform diagnostic criteria based on self-reported prevalence of allergic rhinitis. The use of studies that provided uniform diagnostic criteria for total prevalence of allergic rhinitis facilitated meaningful comparison of the forecast total prevalent cases of allergic rhinitis across the 7MM. Furthermore, Publisher epidemiologists provided a comprehensive forecast of the total prevalent cases of allergic rhinitis segmented by severity (mild, moderate, and severe) as well as type (seasonal, perennial, and both).

Scope

• The Allergic Rhinitis EpiCast Report provide an overview of the risk factors, comorbidities, and the global and historical trends of allergic rhinitis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis segmented by sex and age (ages =18 years).
• The allergic rhinitis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market.
• Quantify patient populations in the global allergic rhinitis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for allergic rhinitis therapeutics in each of the markets covered.

Know more about this report at – http://mrr.cm/Zai

To browse more Healthcare Reports visit:  

http://www.marketresearchreports.com/healthcare

Ebola Viral Infections - Pipeline Review, H1 2014, New Report Launched

Ebola Viral Infections - Pipeline Review, H1 2014 report provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products..

Scope

• The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.
• The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects
• A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Spanning over 70 pages, “Ebola Viral Infections - Pipeline Review, H1 2014” report covering the Introduction, Ebola Viral Infections Overview, Therapeutics Development, Pipeline Products for Ebola Viral Infections - Overview, Pipeline Products for Ebola Viral Infections - Comparative Analysis, Drug Profiles, Appendix, Methodology. The report covered 8 companies - Tekmira Pharmaceuticals Corp., Toyama Chemical Co., Ltd., Medicago Inc., Zalicus Inc., Summit Corporation plc, Vaxart, Inc., Navigen Pharmaceuticals, Inc., Humabs BioMed SA

Know more about this report at – http://mrr.cm/ZaJ

To browse more Diseases Reports visit:  http://www.marketresearchreports.com/diseases

Iron Deficiency Anemia - Pipeline Review, H2 2014, New Report Launched

Iron Deficiency Anemia - Pipeline Review, H2 2014 report provides an overview of the Iron Deficiency Anemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Iron Deficiency Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Iron Deficiency Anemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Iron Deficiency Anemia and enlists all their major and minor projects
• A review of the Iron Deficiency Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Iron Deficiency Anemia pipeline on the basis of target, MoA, route of administration and molecule type

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Iron Deficiency Anemia
• Devise corrective measures for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Spanning over 60 pages, “Iron Deficiency Anemia - Pipeline Review, H2 2014” report covering the Introduction, Therapeutics Development, Pipeline Products for Iron Deficiency Anemia - Overview, Pipeline Products for Iron Deficiency Anemia - Comparative Analysis, Drug Profiles, Appendix and Methodology.

Know more about this report at – http://mrr.cm/Zao

To browse more Pharma and Healthcare Reports visit:  

http://www.marketresearchreports.com/pharma-healthcare

Neutrogin - Drug Insights, 2014, New Report Launched

Neutrogin - Drug Insights, 2014 report provides Neutrogin marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from Publisher proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Publisher team of industry experts.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope

• A review of the Neutrogin based on information derived from company and industry-specific sources
• Coverage of the Marketed data of the Neutrogin on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
• Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Schizophrenia drugs with location details
• Patent Expiry Timeline and Exclusivity Details
• Route of Synthesis of the API
• Global Forecasted Sales Figure from 2011-2015
• Qualitative and quantitative assessment of market space
• SWOT Analysis

Reasons to buy 

• Evaluate the marketing status and exclusivity details of Neutrogin to exploit opportunities for generic drug development opportunities.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Neutrogin.
• API intelligence over Neutrogin and gaining primary intelligence over Active Ingredients manufacturers across the globe.
• Understanding the chemical route of synthesis of Neutrogin.
• Uncovering opportunities in the rapidly growing the US market
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Obtain sales forecast for currently marketed drug for 2011-2015

Spanning over 35 pages, “Neutrogin - Drug Insights, 2014” report covering the Drug Overview, Global API Manufacturers Assessment, The Pipeline Coverage, Company Profile, Summary, SWOT Analysis, Appendix, Methodology.

Know more about this report at – http://mrr.cm/Zbx

Related Reports:

1st - Combivir-Drug Insights, 2014- visit at: http://mrr.cm/Zbf

2nd - Rocephin-Drug Insights, 2014 - visit at: http://mrr.cm/ZbY

3rd - Halaven-Drug Insights, 2014- visit at: http://mrr.cm/Zbg

To browse more market research reports by Delveinsight visit: http://www.marketresearchreports.com/publisher/delveinsight